Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer
| Autor: | Jordan Madic, Aurelie Honore, Etienne Rouleau, Magali Droniou, Benjamin Besse, Cécile Jovelet, Romain Girard, Jordi Remon, Ludovic Lacroix, Barbara André |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male Pathology Lung Neoplasms Physiology Biopsy Gene Identification and Analysis Cancer Treatment lcsh:Medicine Artificial Gene Amplification and Extension medicine.disease_cause Polymerase Chain Reaction Lung and Intrathoracic Tumors law.invention 0302 clinical medicine law Carcinoma Non-Small-Cell Lung Medicine and Health Sciences Digital polymerase chain reaction lcsh:Science Polymerase chain reaction Aged 80 and over Mutation Multidisciplinary Massive parallel sequencing Middle Aged Resistance mutation Body Fluids ErbB Receptors Blood Oncology 030220 oncology & carcinogenesis Physical Sciences Female Anatomy Research Article Adult medicine.medical_specialty Materials by Structure Materials Science Surgical and Invasive Medical Procedures Research and Analysis Methods Crystals Blood Plasma 03 medical and health sciences Carcinoma medicine Genetics Humans Lung cancer Molecular Biology Techniques Mutation Detection Molecular Biology Aged business.industry lcsh:R Biology and Life Sciences Cancers and Neoplasms DNA medicine.disease Circulating Cell-Free DNA Non-Small Cell Lung Cancer 030104 developmental biology Drug Resistance Neoplasm Cancer research lcsh:Q business |
| Zdroj: | PLoS ONE PLoS ONE, Vol 12, Iss 8, p e0183319 (2017) |
| ISSN: | 1932-6203 |
| Popis: | Over the past years, targeted therapies using tyrosine kinase inhibitors (TKI) have led to an increase in progression-free survival and response rate for a subgroup of non-small cell lung cancer (NSCLC) patients harbouring specific gene abnormalities compared with chemotherapy. However long-lasting tumor regression is rarely achieved, due to the development of resistant tumoral subclones, which requires alternative therapeutic approaches. Molecular profile at progressive disease is a challenge for making adaptive treatment decisions. The aim of this study was to monitor EGFR-mutant tumors over time based on the quantity of mutant DNA circulating in plasma (ctDNA), comparing two different methods, Crystal™ Digital™ PCR and Massive Parallel Sequencing (MPS). In plasma circulating cell free DNA (cfDNA) of 61 advanced NSCLC patients we found an overall correlation of 78% between mutated allelic fraction measured by Crystal Digital PCR and MPS. 7 additional samples with sensitizing mutations and 4 additional samples with the resistance mutation were detected with Crystal Digital PCR, but not with MPS. Monitoring levels of both mutation types over time showed a correlation between levels and trends of mutated ctDNA detected and clinical assessment of disease for the 6 patients tested. In conclusion, Crystal Digital PCR exhibited good performance for monitoring mutational status in plasma cfDNA, and also appeared as better suited to the detection of known mutations than MPS in terms of features such as time to results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|